Overall market sentiment has been neutral on Ardelyx Inc (ARDX) stock lately. ARDX receives a Neutral rating from InvestorsObserver Stock Sentiment Indicator.
Ardelyx Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on ARDX!
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With ARDX Stock Today?
Ardelyx Inc (ARDX) stock is trading at $1.13 as of 11:17 AM on Monday, Jan 3, a gain of $0.02, or 2.27% from the previous closing price of $1.10. The stock has traded between $1.07 and $1.16 so far today. Volume today is low. So far 1,824,509 shares have traded compared to average volume of 32,997,671 shares.
To screen for more stocks like Ardelyx Inc click here.
More About Ardelyx Inc
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
Click Here to get the full Stock Report for Ardelyx Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
